CNN —Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.
Medicare began covering Ozempic for people with diabetes in 2018, with Rybelsus and Mounjaro joining in 2019 and 2022, respectively.
The KFF study examined gross spending, which does not take into account any rebates paid by drug manufacturers that would lower Medicare spending.
The drugs’ popularity and prices could end up raising costs for both the federal government and Medicare enrollees broadly.
Medicare could choose Ozempic and Rybelsus for its drug negotiation program as early as 2025, KFF wrote, which could lower spending on the medications.
Persons:
Mounjaro, ” KFF, KFF
Organizations:
CNN, Medicare, US Food and Drug Administration, Congressional